EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial

Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S Lee, Ahmed O Kaseb, Young Nyun Park, Sun-Hee Leem und 3 weitere

Clinical and Molecular Hepatology · 2024

DOI: 10.3350/cmh.2024.0333 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, 2024. Verfasst von Sun Young Yim und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Bevacizumab, Liver Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: The Korean Association for the Study of the Liver, NCI NIH HHS, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Combination immunotherapy, exemplified by atezolizumab plus bevacizumab, has become the standard of care for inoperable hepatocellular carcinoma (HCC). However, the lack of predictive biomarkers and limited understanding of response mechanisms remain a challenge.

Methods

Using data from the IMbrave150plus cohort, we applied an immune signature score (ISS) predictor to stratify HCC patients treated with atezolizumab plus bevacizumab or with sorafenib alone into potential high and low response groups. By applying multiple statistical approaches including a Bayesian covariate prediction algorithm, we refined the signature to 10 key genes (ISS10) for clinical use while maintaining similar predictive power to the full model. We further validated ISS10 in an independent HCC cohort treated with nivolumab plus ipilimumab.

Results

The study identified a significant association between the ISS and treatment response. Among patients classified as high responders, those treated with the atezolizumab plus bevacizumab combination exhibited improved overall and progression-free survival as well as better objective response rate compared to those treated with sorafenib. We also observed a significant correlation between ISS10 and response to nivolumab plus ipilimumab treatment. Analysis of immune cell subpopulations revealed distinct characteristics associated with ISS subtypes. In particular, the ISS10 high subtype displayed a more favorable immune environment with higher proportions of antitumor macrophages and activated T-cells, potentially explaining its better response.

Conclusions

Our study suggests that ISS and ISS10 are promising predictive biomarkers for enhanced therapeutic outcomes in HCC patients undergoing combination immunotherapy. These markers are crucial for refining patient stratification and personalized treatment approaches to advance the effectiveness of standard-of-care regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularBevacizumabLiver NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorHumansMaleSorafenibFemaleImmunotherapyMiddle AgedAgedNivolumab

Stichwörter der Autor:innen

AtezolizumabBevacizumabHepatocellular carcinomaImmunotherapyTranscriptome

Substanzen

BevacizumabatezolizumabAntibodies, Monoclonal, HumanizedBiomarkers, TumorSorafenibNivolumab

Autor:innen und Institutionen

  • Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
  • Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
  • Metabolic Regulation Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Korea.
  • Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Surgery, Korea University Guro Hospital, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Kyung Hee University Hospital at Gangdong, Seoul, Korea.

Förderung

  • The Korean Association for the Study of the Liver
  • NCI NIH HHS
  • National Research Foundation of Korea
  • Ministry of Science and ICT
  • MD Anderson
  • The Korean Liver Foundation
  • NIH HHS
  • Korea University

Zitieren

APA

Yim, S. Y., Lee, S. H., Baek, S. W., Sohn, B., Jeong, Y. S., Kang, S. H., Park, K., Park, H., Lee, S. S., Kaseb, A. O., Park, Y. N., Leem, S. H., Curran, M. A., Kim, J. H., & Lee, J. S. (2024). Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2024.0333

Vancouver

Yim SY, Lee SH, Baek SW, Sohn B, Jeong YS, Kang SH, et al. Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial. Clinical and Molecular Hepatology. 2024. doi:10.3350/cmh.2024.0333

BibTeX
@article{Yim2024,
  author = {Yim, Sun Young and Lee, Sung Hwan and Baek, Seung-Woo and Sohn, Bohwa and Jeong, Yun Seong and Kang, Sang-Hee and Park, Kena and Park, Hyewon and Lee, Sunyoung S and Kaseb, Ahmed O and Park, Young Nyun and Leem, Sun-Hee and Curran, Michael A and Kim, Ji Hoon and Lee, Ju-Seog},
  title = {Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial},
  journal = {Clinical and Molecular Hepatology},
  year = {2024},
  doi = {10.3350/cmh.2024.0333}
}
Kostenlos starten →